Response Genetics (NASDAQ:RGDX) has just announced that it has received approval from the New York State Department of Health to offer, market and report results of its ResponseDX tests to healthcare providers in the State of New York. This is a huge announcement for the company. Why? Well because New York is the third most populated state in the U.S. and the addition of this license to provide testing here will most certainly contribute to the continued growth of the company's ResponseDX sales in 2015. In just the last quarter, the company hit another sales record with its ResponseDX line. I fully expect new sales records in 2015 on the back of this news.
When I covered Response Genetics in depth I laid out a clear analysis showing the turn around the company was undergoing. The last quarter was clearly an indication that the thesis was playing out. However, the stock has clearly moved in the opposite direction of the company. That said, I....READ MORE
No comments:
Post a Comment